Eisai said it’s planning a rolling FDA submission next month to expand the use of its Biogen-partnered subcutaneous Alzheimer’s treatment, the latest effort to stoke

Over the last decade, FDA commissioners have generally steered clear from the nitty-gritty of drug applications, the opinions of drug review staff, or trying to

Eli Lilly’s oral obesity pill orforglipron was among the next six drugs to win the FDA’s National Priority Voucher, offering the GLP-1 drug candidate a

The pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs for diabetes and obesity has arrived.

Since President Donald Trump began his emphatic push to reduce drug prices, a looming question has been how low he could bring down the price